Form D · Biotechnology

NGM Bio Holdings, Inc.

South San Francisco, CA · CIK 0002029767

Offering snapshot reported Mar 27, 2026 · SEC filing

Reported sold: $142M
Investors reported: 26
Minimum accepted: $0
First sale: Jul 5, 2024

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$73,223,979 → $142,039,949
Reported investors25 → 26

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 27, 2026	Amendment	$142,039,949	$68,815,970vs Jul 17, 2024	26	SEC filing
Jul 17, 2024	Initial	$73,223,979	No comparison	25	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-519045

Source: Form D, filed Mar 27, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Diana Peng Bockus	Director, Executive
Kara Calhoun	Executive
David Goeddel	Director
Shelly D. Guyer	Director
Carole Ho	Director
Daniel Kaplan	Executive
Tim Kutzkey	Director
Hsiao D. Lieu	Executive
Roger M. Perlmutter	Director
Valerie Pierce	Executive
William J. Rieflin	Director
Peter Svennilson	Director
Jean Frederic Viret	Executive
David J. Woodhouse	Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

611 Gateway Blvd., Suite 540
South San Francisco, CA, 94080